TTC36 and neoplasm: Building on our findings that TTC36 constrains HCC proliferation via suppressing Ras/MAPK signaling, we hypothesized that high TTC36 level may force tumor cells to rely on alternative proliferation-promoting pathways, thereby inducing resistance to sorafenib.